Tepotinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 231 publications
Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.
Journal: Lung cancer management
Published: April 04, 2026
A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk.
Journal: Renal failure
Published: January 25, 2026
Tepotinib Therapy for Advanced MET Exon 14 Skipping NSCLC With Non-Dialysis End-Stage Renal Disease: A Case Report.
Journal: Respirology case reports
Published: January 05, 2026
Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 18, 2025
Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis.
Journal: Critical reviews in oncology/hematology
Published: December 08, 2025
Real-World Evidence for 10 Oncology Drugs Approved in the last 5 years: A Comprehensive Narrative Synthesis.
Journal: Critical reviews in oncology/hematology
Published: December 08, 2025
Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances.
Journal: Cancers
Published: November 27, 2025
Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.
Journal: Anticancer research
Published: November 19, 2025
Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.
Journal: Scientific reports
Published: October 25, 2025
Tepotinib-Induced Cholangitis in a Patient With Non-Small Cell Lung Cancer: A Case Report.
Journal: Respirology case reports
Published: September 29, 2025
Last Updated: 04/28/2026